Fibromyalgia In Women Research Articles

Prevalence of fibromyalgia: literature review update

The present study aimed to update the literature review on the prevalence of fibromyalgia published in 2006. A bibliographical survey was carried out from 2005 to 2014 in the MEDLINE, Web of Science, Embase, LILACS and SciELO databases and 3274 records were identified. Five researchers selected the studies, following the inclusion criteria: studies that obtained the prevalence of fibromyalgia. Fibromyalgia studies in associated diseases were excluded. When screening by title and abstract, 2073 irrelevant articles were excluded. The full texts of 210 articles were evaluated for eligibility and this review included 39 studies, described in 41 articles. The selected studies were grouped into four categories: (A) prevalence of fibromyalgia in the general population; (B) prevalence of fibromyalgia in women; (C) prevalence of fibromyalgia in rural and urban areas; (D) prevalence of fibromyalgia in special populations. The literature shows values of fibromyalgia prevalence in the general population between 0.2 and 6.6%, in women between 2.4 and 6.8%, in urban areas between 0.7 and 11.4%, in rural areas between 0.1 and 5.2%, and in special populations values between 0.6 and 15%. This literature review update shows a significant increase in fibromyalgia prevalence studies in the world. The new 2010 American College of Rheumatology criteria have not been widely used yet and the COPCORD (Community-oriented program for control of Rheumatic Diseases) methodology has increased the quality of studies on the prevalence of rheumatic diseases in general.

A prevalência de fibromialgia: atualização da revisão de literatura

The present study aimed to update the literature review on the prevalence of fibromyalgia (FM) published in 2006. A bibliographical survey was carried out from 2005 to 2014 in the MEDLINE, Web of Science, Embase, LILACS and SciELO databases and 3274 records were identified. Five researchers selected the studies, following the inclusion criteria: studies that obtained the prevalence of FM. FM studies in associated diseases were excluded. When screening by title and abstract, 2073 irrelevant articles were excluded. The full texts of 210 articles were evaluated for eligibility and this review included 39 studies, described in 41 articles. The selected studies were grouped into four categories: a) prevalence of FM in the general population; B) prevalence of FM in women; C) prevalence of FM in rural and urban areas; D) prevalence of FM in special populations. The literature shows values of FM prevalence in the general population between 0.2 and 6.6%, in women between 2.4 and 6.8%, in urban areas between 0.7 and 11.4%, in rural areas between 0.1 and 5.2%, and in special populations values between 0.6 and 15%. This literature review update shows a significant increase in FM prevalence studies in the world. The new 2010 American College of Rheumatology criteria have not been widely used yet and the COPCORD (Community‐oriented program for control of Rheumatic Diseases) methodology has increased the quality of studies on the prevalence of rheumatic diseases in general.

Independent and joint associations of physical activity and fitness with fibromyalgia symptoms and severity: The al-Ándalus project

ABSTRACTWe examined independent and joint associations of objectively measured physical activity (PA) and physical fitness (PF) with pain, fatigue and the overall impact of fibromyalgia in 386 fibromyalgia women aged 51.2 ± 7.6 years. Levels of PA (light, moderate and vigorous) and PF were measured with triaxial accelerometry and the Senior Fitness Test, respectively. We used the Short-Form health survey-36 pain sub-scale and the Multidimensional Fatigue Inventory to assess pain and multiple dimensions of fatigue, respectively. The impact of fibromyalgia was studied with the Revised Fibromyalgia Impact Questionnaire (FIQR). Both, total PA and global PF were independently associated with pain pressure threshold, SF-36 pain, reduced activity, reduced motivation and FIQR total score (all, P ≤ 0.027). The associations between total PA and symptoms were weaker than those observed between global PF and symptoms. Overall, unfit patients with low PA showed a worse profile that fit patients with high PA (all, P ≤ 0.001). In summary, PA and PF are independently associated with pain, fatigue and the overall impact of fibromyalgia in women. Although PF presented greater associations with symptoms, the results suggest that both being physically active and keep adequate fitness levels might be convenient for fibromyalgia women.

Variability of gait, bilateral coordination, and asymmetry in women with fibromyalgia

PurposeTo analyze how fibromyalgia affected the variability, asymmetry, and bilateral coordination of gait walking at comfortable and fast speeds. Methods65 fibromyalgia (FM) patients and 50 healthy women were analyzed. Gait analysis was performed using an instrumented walkway (GAITRite system). Average walking speed, coefficient of variation (CV) of stride length, swing time, and step width data were obtained and bilateral coordination and gait asymmetry were analyzed. ResultsFM patients presented significantly lower speeds than the healthy group. FM patients obtained significantly higher values of CV_StrideLength (p=0.04; p<0.001), CV_SwingTime (p<0.001; p<0.001), CV_StepWidth (p=0.004; p<0.001), phase coordination index (p=0.01; p=0.03), and p_CV (p<0.001; p=0.001) than the control group, walking at comfortable or fast speeds. Gait asymmetry only showed significant differences in the fast condition. ConclusionFM patients walked more slowly and presented a greater variability of gait and worse bilateral coordination than healthy subjects. Gait asymmetry only showed differences in the fast condition. The variability and the bilateral coordination were particularly affected by FM in women. Therefore, variability and bilateral coordination of gait could be analyzed to complement the gait evaluation of FM patients.

The association of total and central body fat with pain, fatigue and the impact of fibromyalgia in women; role of physical fitness.

The relationship between estimates of total and central body fat with fibromyalgia pain, fatigue and overall impact has not been fully described. We aimed to assess the individual and combined association of body fat (total and central) with pain, fatigue and the overall impact in fibromyalgia women; and to study the possible mediation role of physical fitness in these associations. A total of 486 fibromyalgia women with a mean (standard deviation) age of 52.2 (8.0) years participated. Pain was measured with self-reported measures and algometry, whereas fatigue with the Multidimensional Fatigue Inventory. The impact of fibromyalgia was measured with the Revised Fibromyalgia Impact Questionnaire (FIQR) total score. Total and central body fat were assessed by means of bioelectrical impedance and waist circumference, respectively. The Functional Senior Fitness Test battery and the handgrip strength test were used to assess physical fitness. Total and central body fat were positively associated with pain- and fatigue-related measures and the FIQR total score (β from 0.10 to 0.25; all, p<0.05). A combined effect of total and central body fat was observed on pain (FIQR and 36-item Short-Form Health Survey), general and physical-related fatigue and FIQR total score (all, overall p<0.05), so that the group with no total and central obesity had more favourable results than those with total and central obesity. Cardiorespiratory fitness partially mediated (between 22-40% of the total effect) the associations between total and central body fat with pain, general fatigue, physical fatigue and reduced activity, and largely mediated (80%) the association of central body fat with the FIQR total score. Physical fitness might potentially explain the association between obesity and fibromyalgia symptoms.

Effect of Exercise Programs on Symptoms of Fibromyalgia in Peri-Menopausal Age Women: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Objectives: The aim of this review and meta-analysis was to summarize evidence regarding the effect of physical exercise programs on fibromyalgia syndrome symptoms in peri-menopausal age women, and the characteristics of these programs.Findings: Nineteen randomized controlled trials [N = 1077 women] satisfied the inclusion criteria. Methodological quality of papers was assessed using the PEDro scores. Data on the study, subject, and exercise program characteristics as well as assessment of changes in depression, fatigue, global well-being [overall feeling of well-being and health-related quality of life], pain, sleep, and stiffness were extracted. The studies were grouped according to the intervention program: land interventions [aerobic, combined [aerobic endurance, strength, and flexibility], vibrations, and alternative programs], and aquatic interventions. Nineteen studies were selected for systematic review, but clinical heterogeneity limited the meta-analysis to two aerobic, three combined, two alternative, and five aquatic studies.Conclusions: In general, exercise programs have a positive effect on the symptoms of fibromyalgia in women in peri-menopausal age. The meta-analysis indicates that programs based on combined exercise and aquatic exercises have, respectively, a moderate [d = −0.63; I2 = 0%] and small effect [d = −0.41; I2 = 30%] on functional global well-being [assessed using the Fibromyalgia Impact Questionnaire total score]. Short-term interventions [12 weeks], including two to three sessions lasting 30–60 min each per week seem to improve symptoms in peri-menopausal age women with fibromyalgia, although high-quality studies with larger sample sizes are necessary to confirm these results.

Fitness testing in the fibromyalgia diagnosis: the al-Ándalus project.

This study aimed to determine the ability of a set of physical fitness tests to discriminate presence or absence of fibromyalgia in women. The sample comprised 487 women with fibromyalgia (52.1 ± 8 yr) and 250 control women (49.3 ± 9 yr). We assessed physical fitness using the arm curl, 30-s chair stand, handgrip strength, 8-ft up and go, 6-min walk, chair sit and reach, and the back scratch tests. The revised fibromyalgia impact questionnaire was used to assess fibromyalgia severity and symptomatology. Patients with fibromyalgia performed worse than control women in all the fitness tests studied (all, P < 0.001). The receiver operating characteristic analysis showed that all the fitness tests were able to discriminate between presence and absence of fibromyalgia (all, P < 0.001). The area under the curve ranged from 0.708 to 0.910 (all, P < 0.001). Among the fitness tests studied, the arm curl test, followed by the 30-s chair-stand and handgrip strength tests, showed the highest capacity discriminating between the presence and absence of fibromyalgia. An arm curl test score of <20 repetitions was associated with increased odds of having fibromyalgia (odds ratio (OR), 35.6; 95% confidence interval, 12.6-101) in women age 35-44 yr. An arm curl test score of <16 repetitions was associated with increased odds of having fibromyalgia (OR, 23.7; 95% confidence interval, 10.3-54.0) in women age 35-44 yr. In the group of women age 55-65 yr, the highest OR was observed for the handgrip strength test and the odds of having fibromyalgia was 17 times greater than that in patients who performed less than 19 kg. The arm curl, 30-s chair stand, and handgrip strength tests powerfully discriminated women with fibromyalgia from healthy women. Identification of women who fail to meet the suggested standards can help to easily, quickly, and cheaply rule out the presence of the disease, especially in primary care settings.

Men and women with fibromyalgia: Relation between attentional function and clinical symptoms.

This study was the first to explore whether individuals with fibromyalgia (FM) have different cognitive alterations (i.e., in alertness, orienting, and executive control) depending on their sex. We also analysed possible gender differences in the relationships between cognitive functioning and some of the main symptoms of FM. Cross-sectional study. Two clinical groups with FM (n = 58 women and n = 20 men) and two healthy control groups (n = 21 women and n = 27 men) aged between 30 and 60 years old participated in this study. Pain intensity, sleep disturbance, depression, anxiety, pain catastrophizing, and daily functioning were evaluated with self-report measures. Attentional function was assessed with the ANT-I task (Attentional Network Test-Interactions). Mixed ANOVAs showed impairment in vigilance and executive control in both male and female patients with FM compared with controls. Control men were faster than control women, but FM eliminated sex differences. In addition, attention deficit was associated with worse daily functioning in women but not in men with FM. Emotional distress and sleep disruption seemed to contribute differently to these cognitive alterations in both sexes. Therapy strategies aimed at reducing emotional distress and sleep disruption are likely to improve cognitive function by enhancing vigilance. Therapies aimed at reducing emotional distress seem to improve attentional function more in women than in men; those aimed at improving sleep quality are likely to reduce a vigilance/alertness deficit in women and executive problems in men.

Does fibromyalgia influence symptom bother from pelvic organ prolapse?

Determine if women with fibromyalgia report increased bother from pelvic organ prolapse compared with women without fibromyalgia. We performed a cross-sectional study of women with symptomatic prolapse on consultation with a private urogynecology practice within a 46-month period. After matching for age, women with a diagnosis of fibromyalgia were compared with a reference group of women without fibromyalgia. Demographic, POPQ examination, medical history, and pelvic floor symptom data (PFDI, PFIQ, and PISQ-12) were collected. Our primary outcome was to compare the mean Pelvic Floor Distress Inventory (PFDI) scores of women with and without fibromyalgia. The prevalence of fibromyalgia in women evaluated for initial urogynecology consultation during the study period was 114 out of 1,113 (7%). Women with fibromyalgia reported significantly higher symptom bother scores related to pelvic organ prolapse, defecatory dysfunction, urinary symptoms, and sexual function: PFDI (p = 0.005), PFIQ (p=0.010), and PISQ (p=0.018). Women with fibromyalgia were found to have a higher BMI (p=0.008) and were more likely to report a history of sexual abuse, OR 3.1 (95 % CI 1.3, 7.9), and have levator myalgia on examination, OR 3.8 (95% CI 1.5, 9.1). In a linear regression analysis, levator myalgia was found to be the significant factor associated with pelvic floor symptom bother. In women with symptomatic prolapse, fibromyalgia is associated with an increased risk of levator myalgia and 50% more symptom bother from pelvic floor disorders.

Fibromyalgia: antecedent life events, disability, and causal attribution

This study aimed to evaluate the relation of disability and physical and mental health status with potentially traumatic life events (PTLE) before the onset of fibromyalgia in women diagnosed with this syndrome. We also investigated causal attribution of fibromyalgia to a triggering event, physical or psychological in nature, and its relation with the health measures and the adverse life events. The impact of fibromyalgia, physical and mental health status, pain, PTLE in childhood and not in childhood, and causal attribution were assessed in a sample of 50 women with fibromyalgia, aged 25–70 (M = 46.96; SD = 10.96). There were no statistically significant relations between the health measures (disability, physical and mental health, and pain) and the PTLE. The predominant attribution was to a physical event. There were no significant differences neither in the health measures across causal attribution status (Pillai’s Trace = 0.193; F(8,90) = 1.200; p = .308; η 2 par = .096) nor in the PTLE not in childhood (F(2,47) = 1.063; p = .354; η 2 par = .043). There were significant differences across causal attribution status in the PTLE in childhood (F(2,47) = 3.590; p = .035; η 2 par = .133), specifically between the group that made a psychological attribution and the group that made no attribution (C.I. 95%) 0.1805; 14.0468; (p = .043), with the former having a higher score of PTLE in childhood. The results raise questions about the importance of psychological aspects in the appraisal of the adverse events and its possible relation to the psychological functioning in women with fibromyalgia.

Strong links discovered between sleep problems and fibromyalgia in women

Strong links discovered between sleep problems and fibromyalgia in women

The Association Between Incident Self-reported Fibromyalgia and Nonpsychiatric Factors: 25-years Follow-up of the Adventist Health Study

The purpose of the study was to investigate the association between incident self-reported fibromyalgia (FM) and prior somatic diseases, lifestyle factors, and health behaviors among 3,136 women who participated in 2 cohort studies 25 to 26 years apart (the Adventist Health Study 1 and 2). The women completed a comprehensive lifestyle and medical history questionnaire at baseline in 1976. Information on new diagnosis of doctor-told FM was obtained at the second survey in 2002. A total of 136 women reported a diagnosis of FM during 25 years of follow-up, giving a period incidence of 43/1,000 or 1.72/1000 per year. In multivariable logistic regression analyses, a significant, dose-response association was found with number of allergies with OR of 1.61 (95% CI: .92-2.83) and 3.99 (95% CI: 2.31-6.88), (P[trend] < .0001), respectively, for 1 and 2 or more allergies versus none. A history of hyperemesis gravidarum was also associated with FM with OR of 1.32 (95% CI: .75-2.32) and 1.73 (95% CI: .99-3.03), (P[trend] < .05), respectively, for some or all pregnancies versus none. A positive association with smoking was also found with OR of 2.37 (95% CI: 1.33-4.23) for ever smokers versus never smokers. No significant association was found with number of surgeries, history of peptic ulcer, or taking medications to control various symptoms. Smoking as well as prevalent allergies, and a history of hyperemesis gravidarum, seem to predict development of FM in women during 25 years of follow-up. This information may help in identifying persons at high risk of developing FM and thus initiate effective prevention strategies.

Fibromyalgia: Diagnosis and treatment options

Fibromyalgia is a widespread, chronic pain disorder that includes a complex constellation of somatic and emotional symptoms. Controlled clinical trials for both medication and nonmedication therapies have led to sound, evidence-based recommendations for the care of patients with fibromyalgia. This review article was designed to provide updated information from database literature searches on fibromyalgia epidemiology, including gender differences, psychological comorbidity, and treatment with medication and nonmedication therapies. A literature review was performed by identifying fibromyalgia articles published in English from January 2000 to October 2008 using the PubMed and EMBASE databases. Search terms included fibromyalgia, exercise, gender, nonpharmacologic, placebo-controlled, randomized, and treatment. New epidemiologic data support important differences in fibromyalgia symptom severity between the sexes and the important role of comorbid psychological distress. Physicians diagnose fibromyalgia in women at an approximately 3- to 6-fold rate compared with men. Well-conducted clinical trials and recently published treatment guidelines reinforce effective treatment with medication and nonpharmacologic therapy. The strongest evidence suggests effective treatment of fibromyalgia with duloxetine and milnacipran. Studies also report efficacy with gabapentin, pramipexole, pregabalin, tramadol, and IV tropisetron. Nonpharmacologic treatments should include fitness and strengthening exercise, as well as warm-water therapy and psychological pain management techniques. Fibromyalgia is a common, disabling, chronic pain condition that predominantly affects women. Symptoms can be effectively treated using both drug and nondrug therapies. In general, treatment benefits in fibromyalgia appear largely independent of patient sex.

Cost-utility of an 8-month aquatic training for women with fibromyalgia: a randomized controlled trial

IntroductionPhysical therapy in warm water has been effective and highly recommended for persons with fibromyalgia, but its efficiency remains largely unknown. Should patients or health care managers invest in this therapy? The aim of the current study was to assess the cost-utility of adding an aquatic exercise programme to the usual care of women with fibromyalgia.MethodsCosts to the health care system and to society were considered in this study that included 33 participants, randomly assigned to the experimental group (n = 17) or a control group (n = 16). The intervention in the experimental group consisted of a 1-h, supervised, water-based exercise sessions, three times per week for 8 months. The main outcome measures were the health care costs and the number of quality-adjusted life-years (QALYs) using the time trade-off elicitation technique from the EuroQol EQ-5D instrument. Sensitivity analyses were performed for variations in staff salary, number of women attending sessions and time spent going to the pool. The cost effectiveness acceptability curves were created using a non-parametric bootstrap technique.ResultsThe mean incremental treatment costs exceeded those for usual care per patient by € 517 for health care costs and € 1,032 for societal costs. The mean incremental QALY associated with the intervention was 0.131 (95% CI: 0.011 to 0.290). Each QALY gained in association with the exercise programme cost an additional € 3,947/QALY (95% CI: 1,782 to 47,000) for a health care perspective and € 7,878/QALY (3,559 to 93,818) from a societal perspective. The curves showed a 95% probability that the addition of the water-based programme is a cost-effective strategy if the ceiling of inversion is € 14,200/QALY from a health care perspective and € 28,300/QALY from a societal perspective.ConclusionThe addition of an aquatic exercise programme to the usual care regime for fibromyalgia in women is cost effective in terms of both health care costs and societal costs. However, the characteristics of facilities (distance from the patients' homes and number of patients that can be accommodated per session) are major determinants to consider before investing in such a programme.Trial registrationCurrent controlled trials ISRCTN53367487.

Duloxetine for the Treatment of Fibromyalgia in Women: Pooled Results from Two Randomized, Placebo-Controlled Clinical Trials

To assess the efficacy (in particular, in pain, functional impairment, and quality of life) and safety and tolerability (incidence of adverse events, discontinuation rates, changes in laboratory findings, and vital signs) of duloxetine in female patients with fibromyalgia. Data were pooled from two placebo-controlled clinical trials of similar design (randomized, 12-week, and double-blind), comparing duloxetine 60 mg a day (q.d.) or 60 mg twice daily (b.i.d.) (n = 326) with placebo (n = 212), in women who met the American College of Rheumatology criteria for primary fibromyalgia. Compared with the patients receiving placebo, duloxetine-treated female patients demonstrated a significantly greater improvement in the Brief Pain Inventory (BPI) average pain severity score and in the Fibromyalgia Impact Questionnaire (FIQ) total score, beginning at week 1 and continuing through week 12 (p < 0.001). Duloxetine was superior to placebo on all efficacy measures, including mean tender point threshold, Clinical Global Impression of Severity, Patient Global Impression of Improvement, and average interference from pain scores. The duloxetine-treated group was superior to placebo on all quality of life and functional measures, including each domain of the Medical Outcomes Study Short Form-36 (SF-36). A direct treatment effect of duloxetine on pain reduction was demonstrated and shown to be independent of secondary improvement in mood (based on BPI average pain score). Significantly more duloxetine-treated patients reported treatment-emergent adverse events (296 [90.8%] duloxetine-treated and 165 [77.8%] placebo-treated, p < 0.001). Rates of serious adverse events were similar between duloxetine-treated and placebo-treated patients. The pooled results of these studies demonstrate that duloxetine is a safe and efficacious treatment for both the pain and functional impairment associated with fibromyalgia in female patients, while significantly improving quality of life.

Fibromyalgia in women with ankylosing spondylitis

Fibromyalgia (FM), pre-dominantly found in women, may accompany other pre-existing rheumatic diseases. The association between FM and ankylosing spondylitis (AS) is uncertain. We evaluated FM in women with AS. Eighteen women with AS were compared with 18 men with AS (controls) for age, duration of symptoms, time to diagnosis, degree of sacroiliac involvement, history of peripheral arthritis, patient global assessment, Health Assessment Questionnaire, Fibromyalgia Impact Questionnaire, level of diffuse pain, Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), and Bath Ankylosing Spondylitis Functional Index (BASFI). Physical examination included the number of tender points and enthesitis sites, Schober test, distance between occiput and wall, chest expansion, lateral spinal flexion, and intermalleolar distance. Inflammatory activity was measured by the erythrocyte sedimentation rate (ESR). Of all tested parameters, the ones with significant differences between the groups were time between symptom onset and AS diagnosis (longer for women), FM incidence and the number of tender points and enthesitis sites (higher for women), BASDAI (higher in women and correlated with FM and the number of tender points but not with ESR), and BASFI and BASDAI scores (increased in FM patients). FM was present in 50% of women with AS and associated with higher disease activity indices (BASDAI and BASFI) and not related to severity of physical findings or ESR. The reliability of well-accepted assessment tools of AS, such as BASDAI and BASFI, in evaluating AS activity in women may be called into question due to a confounding effect of FM.

The diagnosis of fibromyalgia in women may be influenced by menstrual cycle phase

Summary This investigation evaluated changes in pressure pain threshold (PPT) in 11 healthy females during three phases of the menstrual cycle: menstrual (day 3 following onset of menses), follicular (days 12–13), and luteal (day 21). PPTs were measured with an algometer at nine anatomical locations, bilaterally, for a total of 18 sites. The sites chosen serve as one criterion for the diagnosis of fibromyalgia, which requires the presence of tenderness at ⩾11 of these sites, with a PPT of ⩽4kg. When measured as a continuous variable over the course of two sequential menstrual cycles, mean PPT measurements during the menstrual phase (3.40±1.12kg), follicular phase (3.44±1.17kg), and the luteal phase (3.56±1.14kg) were not statistically significant. However, when PPT data were converted to dichotomous, discrete variables (either ⩽4 or >4kg), five participants changed fibromyalgia diagnosis during the course of a menstrual cycle, fulfilling the PPT criterion (⩽4kg at ⩾11 points) during the luteal phase ( n =3) or menstrual phase ( n =2), but never during the follicular phase. We compare these results with previous studies, and discuss influences upon PPT by hormonal fluctuations, the endorphin system, and the endocannabinoid system. In summary, clinicians should appreciate that sensitivity to pressure and pain varies over the course of the menstrual cycle, requiring clinical adjustments in palpation-based diagnostic models and treatment modalities.

PR_186: Duloxetine in the Treatment of Fibromyalgia in Women: Results From 2 Clinical Trials

Objective: To assess the efficacy of duloxetine on reduction of pain severity in women with primary fibromyalgia, with or without major depressive disorder (MDD). Design: Two 12-week randomized, double-blind, placebo-controlled trials. Setting: University and clinical trial research sites, pain clinics, rheumatologists, and psychiatric sites. Participants: Adult outpatients met American College of Rheumatology criteria for primary fibromyalgia. Interventions: Study 1: 60mg of duloxetine twice daily (DLX60BID) (N=92) versus placebo (N=92).

A prevalência de fibromialgia: uma revisão de literatura

RESUMO INTRODUÇÃO E OBJETIVO: este trabalho teve como objetivo realizar uma revisão da literatura sobre a prevalência da fibromialgia (FM) na população a partir dos critérios propostos pelo American College of Rheumatology (ACR). MÉTODOS: foi realizado levantamento bibliográfico do período de 1990 a 2005 nas bases de dados MedLine, Lilacs, Embase e ISI. Foram utilizadas as palavras-chave "fibromialgia" e "prevalência" e as correspondentes em inglês, "fibromyalgia" e "prevalence". Foram selecionados 97 artigos e, após leitura dos resumos, foram excluídos os que se referiam à prevalência em doenças. Somente 30 abordavam o tema prevalência da fibromialgia na população. Os artigos selecionados foram agrupados em cinco categorias: a) prevalência da FM em populações adultas; b) prevalência da FM em mulheres; c) prevalência da FM em crianças e adolescentes; d) prevalência da FM em populações específicas; e) prevalência de dor crônica e difusa na população, segundo os critérios do ACR. RESULTADOS: a literatura aponta a prevalência da FM na população com valores entre 0,66 e 4,4%, sendo mais prevalente em mulheres do que em homens, especialmente na faixa etária entre 35 e 60 anos. Os estudos com crianças e adolescentes e em grupos especiais são escassos e pouco conclusivos. A prevalência de dor crônica difusa na população em geral também tem poucos estudos, com valores entre 11 e 13%. CONCLUSÃO: mais estudos sobre prevalência de dor crônica e difusa devem ser estimulados, assim como os de prevalência na população adulta, crianças e jovens.

Myofascial pain and fibromyalgia: Coping with fibromyalgia in women with a history of childhood abuse

Myofascial pain and fibromyalgia: Coping with fibromyalgia in women with a history of childhood abuse